Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Get Willis Owens to issue a share cert, they will be getting a list of entitlement and holders they have accounts for. Ask other brokers if they can accept the share certificate into an account for yourself.
BB
CFW: I posted this yesterday from Corporate actions.
Effective date: 29th November 2021
Terms: 1 US Accustem share in exchange for every 20 UK Accustem shares held
Pay date: Upon receipt
The Board of Accustem has announced its intention to enter into a Scheme of Arrangement whereby Accustem Sciences Limited (the UK company in which you currently hold unlisted shares) will be incorporated into Accustem Sciences Inc (a US incorporated company, for which the Board intend to seek a NASDAQ listing), subject to shareholder approval at a meeting to be held on 18th November 2021. Under the terms of the Scheme, your UK Accustem shares will be converted into US Accustem shares, and these will be consolidated on a 1-for-20 basis, such that you will receive 1 US Accustem share for every 20 UK Accustem shares currently held.
I imagine you will be issued a shares certificate if you cannot hold US stocks in your account.
Court Meeting 11:00 a.m. on 18 November 2021
Scheme General Meeting 11:15 a.m. on 18 November 2021
The following dates are subject to change:
Last time for dealings in, for registration of transfers of, and D&I disablement in CREST of UK Accustem Shares
Close of business on 24 November 2021
Court Hearing to sanction the Scheme 25 November 2021
Scheme Record Time Close of business on 26 November 2021
Scheme Effective Date 8:00 a.m. on29 November 2021
BB
CFW:
From who!
I imagine there must have been prior notice of a deadline.
BB
The shares should be in suspension until all shareholders are able to trade.
BB
From !!:
]CORPORATE ACTION NOTICE
Important information about your stock 17 November 2021
A corporate action is taking place in relation to ACCUSTEM SCIENCES (stock code BNT2JT9), which you currently hold in your portfolio (a/c 0988934).
What is happening?
Scheme of Arrangement & Consolidation
Effective date: 29th November 2021
Terms: 1 US Accustem share in exchange for every 20 UK Accustem shares held
Pay date: Upon receipt
The Board of Accustem has announced its intention to enter into a Scheme of Arrangement whereby Accustem Sciences Limited (the UK company in which you currently hold unlisted shares) will be incorporated into Accustem Sciences Inc (a US incorporated company, for which the Board intend to seek a NASDAQ listing), subject to shareholder approval at a meeting to be held on 18th November 2021. Under the terms of the Scheme, your UK Accustem shares will be converted into US Accustem shares, and these will be consolidated on a 1-for-20 basis, such that you will receive 1 US Accustem share for every 20 UK Accustem shares currently held. The company have stated that fractional proceeds will not be issued for holders whose UK Accustem
share quantity is not exactly divisible by 20.
Once the Scheme has become effective, your existing UK shares will be removed from your account. New US shares will only be credited once we receive holding statements from the company. This is expected to be within 14 days of the effective date, but this timescale cannot be guaranteed. The Board intends to seek admission for the new US Accustem shares to be admitted to trading on NASDAQ. They have stated that this is expected to happen in early 2022. If and when this occurs, we will seek to move your shares from statement form to our international custodian so that you can trade them via our platform. This process can take some
time and you may not be able to trade the shares until several weeks after any NASDAQ submission goes live.
Please note, as a consequence of this Scheme, our previous announcement offering to convert your shares to Accustem American Depository Receipts (ADRs) will no longer go ahead and existing elections to convert will be disregarded. This is because the company intends to cease its ADR programme and convert existing ADRs to US ordinary shares, as part of the Scheme proposals.'
So tradeable only after several weeks from listing & if you elected to sell - it won't go ahead (I didn't )
BB
The SEC complaint was directed at the TLSA delay, not Accustem listing issue.
BB
I have just submitted an SEC complaints form.
AS there are no responses from the company when emailed. It may cause them to supply an update when contacted by SEC.
'Thank you for submitting your online contact to the U.S. Securities and Exchange Commission's Office of Investor Education and Advocacy.'
BB
From II: Comment: PLEASE NOTE THAT THIS IS AN AMENDMENT TO MEETING ID 648327 DUE TO RECEIPT POSTPONEMENT OF MEETING DATE FROM 04 NOV 2021 TO 18 NOV 2021. ALL VOTES RECEIVED ON THE PREVIOUS MEETING WILL BE DISREGARDED AND YOU WILL NEED TO REINSTRUCT ON THIS MEETING NOTICE. THANK YOU.
It still says to be received by 12th Nov. Message received on the 16th Nov.
A right Fuster Cluck!
BB
Can the Corporate action team make a complaint on behalf of the shareholders who have not received their shares as per the Project Jupiter Document filed by Tiziana. They have failed to carryout there own instructions. Copied here: 'As soon as practicable and, in any event, no later than 14 days after the Scheme Effective Date, Computershare will mail a statement by first class mail to each Scheme Shareholder holding Scheme Shares in uncertificated form providing evidence of ownership of the New Tiziana Shares such Scheme Shareholder holds.' Can our Corporate Actions Team contact Computershare, so they can tell you when these shares will now be issued and tradeable. TYIA
BB
Is this being driven down due to the next fund raise being required, or just to allow II's a seat at the table. We are at 25% of the previous raise. There can't be much trust for GC's plans of the last 18 months as most targets have been missed or delayed substantially and the money appears to decay with no actions /trials occurring. On the surface, it is looking like a lifestyle company. What have the following been doing?
'Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company's pre-clinical and clinical drug development programs and associated intellectual property.'
'Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics - Dr Graham was VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., where he managed and oversaw a large portion of the Regeneron pipeline portfolio including leading the immunology and inflammation antibody products across all stages of development from preclinical to post-launch'.
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs.
'Dr. Schutz has over 19 years of pharmaceutical industry experience including 14 years of Regulatory Affairs experience. He has focused on disease indications with high unmet medical needs, in Neurology (including multiple sclerosis), Pulmonology (including infectious disease), and other potential disease indications, which the Company is currently developing products for or is planning to pursue. Specifically, Foralumab (an intranasally delivered, next generation, fully human anti-CD3 monoclonal antibody) for Secondary Progressive Multiple Sclerosis (SPMS) and COVID-19 with Pulmonary Inflammation as lead indications.'
It would be good to get an update on what all these extra Board members have been getting up to.
They all look superb on paper, but they don't come for free!
BB
Whilst the majority of shareholders cannot trade their shares.
BB
FIREGUYUK: So they want 20 of our UK shares for only 1 US share
They want 20 UK shares for only 1 new US listed share.
They also want 10 US Old shares (ADR's) for 1 new listed US share.
So the new shares would trade today at 10 x the Accustem OTC pinks price - $2.12
BB
What will it be?
BB
Understood
Cheers LDJ
BB
Leddachjack: Have just transfered them all out of my ISA into my trading account. Guess I may lose about 500 quid short term but feel happier myself just running with it !!
Why do you lose £500 due to the transfer to your trading account?
I have transferred my 30,000 Accustem shares to my trading account from my ISA.
BB
$0.05/ADR is a very high charge when the ADR's are trading at $0.235 SP
If there is a similar charge for the new Accustem shares, at least you will have a 90% reduction in that fee.
30,000 divided by 2 = 15,000 ADR's currently
or
30,000 divided by 20 = 1500 new Accustem shares
BB
Your Uk Accustem shares will get{:
1 current ADR shares for 2 uk Accustem shares held, they are then sold and cash minus fees credited to your account.
If you hold you will get 1 new Accustem share for every 20 uk Accustem held . These may not be tradeable initially and could be removed from your ISA/SIPP, at worse you could get a share certificate (guessing).
If you currently hold ADR's, you will receive 1 new Accustem share for every 10 ADR's. These again, may not be tradeable initially and could be removed from your ISA/SIPP, at worse you could get a share certificate.
All IMHO
BB
Make that $750
& $75
Even more of a saving.
BB
At the moment I have 30,000 shares costing $375 to change to 15,000 ADR's plus fees.
After 1:20 consolidation I will have 1500 ADR's and $37.50 plus fees.
I think I'll take the default option and see where this goes.
They may be removed from my ISA, but I can't see any capital gains tax implications on 1500 shares in the near term.
BB
SJ1
It was reported to shareholders how the process would go. However the Nasdaq hasn't improved anything wrt TLSA SP. I see 4D had a nice rise on no news (50%). Hoping for similar rise here one day!
BB